NCT03220074

Linezolid for Treatment of Nontuberculous Mycobacterial Diseases

Efficacy and Tolerability of Linezolid for Treatment of Nontuberculous Mycobacterial Diseases

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Mahidol University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A prospective open study to determine the efficacy and tolerability of oral linezolid 600mg./day for the treatment of 40 patients with nontuberculous mycobacterial diseases will be conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Detailed description

This will be an open label clinical study of oral linezolid combination with another oral antimycobacterial drug as the maintenance treatment of nontuberculous mycobacterial diseases in adult. The eligible patients will be treated and monitored for the efficacy and safety every 6 weeks until 6 months then every 3 months for a total duration of 18 months.

Conditions

• Non-tuberculous Mycobacterial Infections

Interventions

Type	Name	Description
DRUG	Oral Tablet	study drug given and monitored for efficacy and tolerability

Timeline

• Start date: 2017-12-15
• Primary completion: 2021-06-15
• Completion: 2022-06-15
• First posted: 2017-07-18
• Last updated: 2024-11-20

Locations

1 site across 1 country: Thailand